Sarcoma News

The daily combination of sirolimus with cyclophosphamide every other week appeared safe and well tolerated by most patients with advanced sarcoma who had undergone standard chemotherapy, according to study results.

Patients with soft tissue sarcoma who achieved an early PET response after a single cycle of neoadjuvant chemotherapy experienced significantly longer survival compared with those who did not achieve an early PET response, according to study results.

The VEGF inhibitor pazopanib increased PFS in patients with metastatic soft-tissue sarcoma and may represent a new treatment option for this rare disease, according to the results of the PALETTE study.

A combination of two targeted therapies showed evidence of tumor regression in patients with treatment-resistant Ewing’s sarcoma or desmoplastic small round cell tumors, according to recent study results. Researchers enrolled 20 patients in a phase 1 trial to evaluate the combination of cixutumumab, a human immunoglobulin G1 monoclonal antibody that targets insulin-like growth factor I receptor, and the mTOR inhibitor temsirolimus.

An FDA panel rejected ridaforolimus as a maintenance therapy for patients with soft-tissue or bone sarcoma.

An FDA panel overwhelmingly expressed its support for the approval of pazopanib for patients with advanced soft tissue sarcoma who previously underwent chemotherapy.

Tumor and patient characteristics that can predict prognosis after resection of retroperitoneal sarcoma lose their significance after 1 year of survival, according to study findings published in Cancer.

A 23-year-old female with no significant medical history developed a headache. On the evening of the following day, the headache was accompanied by nausea and vomiting. Her mother discovered her having a seizure the following morning and brought her immediately to the ED. She had another seizure and vomited upon arrival to the ED, and shortly thereafter, she was sent for a noncontrast head CT. An MRI was acquired 2 days later. Several days after these imaging studies, the patient underwent surgery.

Each year in the United States between 1,500 and 1,700 children are diagnosed with a bone or soft tissue sarcoma, making up about 15% of cancers in youth aged younger than 20 years. However, pediatric cancers themselves are rare and comprise only about 1% of cancer cases.

The discovery of hyperactive signals along the Wnt pathway in human sarcoma cells by researchers at Mount Sinai School of Medicine could lead to new targeted sarcoma treatments.